Merck Receives FDA Approval for IDVYNSO, Expands Oncology Pipeline and Animal Health Sales
Merck has received U.S. FDA approval for IDVYNSO, a once-daily oral treatment for certain adults with virologically suppressed HIV-1.
Therapeutic Area
Therapeutic area intelligence for HIV-1 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.